Can a single gene infusion rebuild failing hearts?
NCT ID NCT04179643
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new gene therapy called AB-1002 in people with advanced heart failure (NYHA Class III). The therapy is given as a single infusion directly into the heart's blood vessels, aiming to deliver a gene that may help heart muscle pump more effectively. The study includes about 11 participants with non-ischemic cardiomyopathy and will measure changes in exercise capacity and heart function over a year, with longer-term follow-up by phone. The goal is to see if this approach is safe and shows promise for improving heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AB-1002, a gene therapy delivered directly to the heart via a single infusion into the coronary arteries
- What this could lead to
- If successful, this could lead to a new treatment that improves heart function and quality of life for people with advanced heart failure, potentially reducing the need for more invasive interventions.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. Gene therapy carries risks such as immune reactions or unintended effects on the heart, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Minneapolis Heart Foundation Institute
Minneapolis, Minnesota, 55407, United States
-
The Linder Center for Education and Research at The Christ Hospital
Cincinnati, Ohio, 45219, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Wisconsin at Madison
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Can better healthcare access save hearts after prison?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?